Direct Answer: AI Should Flag Claims, Not Automatically Deny Them
An insurer should treat an AI fraud score as an investigative signal, not as proof that a claimant committed fraud. By 26 September 2026, insurers use machine learning to detect duplicate invoices, inconsistent injury histories, suspicious billing patterns, unusual claim frequency, network anomalies, and document anomalies, but the reliability of those signals depends on the data, model, and claim involved. A useful review process separates four decisions: automated data capture, algorithmic prioritization, human investigation, and final claim adjudication. The first two can be automated under controlled conditions; the last two still require trained staff, access to the underlying evidence, and an opportunity for the policyholder to respond. This distinction is particularly important because false positives can delay legitimate care, increase premiums, deny medically necessary treatment, or expose an insurer to bad-faith and discrimination claims. The proper standard is therefore not whether AI can identify fraud, but whether its findings are accurate, explainable, consistently tested, and proportionate to the claim’s value and complexity.
Also worth reading: What Are the Best Insurance Fraud Detection Tools for Claimants, Insurers, and AI Brokers in 2026? · How Do Insurers Actually Use AI to Detect Fraud in 2026? · What Controls Should Insurers Use for AI Underwriting Decisions in 2026?
A sound policy should prohibit adverse action based solely on a model score, a proprietary “red flag,” or an unreviewed third-party blacklist. Humans must be able to see the principal evidence behind the alert, challenge an incorrect result, request missing records, and document why the finding was accepted or rejected. Low-value claims may receive streamlined handling, while high-value, sensitive, clinically complex, or legally delicate claims should receive more intensive review. Regulators are already paying attention to automated claims processes: KFF has examined federal and state consumer protections governing AI in prior authorization and claims review, while public-sector examples in Washington and Arizona show that government payers face the same governance pressure. AI may improve consistency and speed, but it does not transfer the insurer’s legal responsibility to the model developer.
How AI Fraud Detection Works in Insurance Claims
Claims-fraud systems generally assign a probability or risk score instead of producing a definitive verdict. They compare a claim with historical data, policy details, provider information, billing codes, prior claims, treatment records, and other transactions to locate unusual combinations. Some systems use rules that flag a provider for submitting six or more impossible dates; others use machine learning to identify a pattern that may not have been anticipated by a human analyst. In healthcare claims, algorithms may examine diagnosis codes, dates of service, prescription patterns, duplicate billing, and relationships among patients, clinicians, and facilities. The result might be a score of 0.87, but that number normally means the model estimated a relative likelihood under its training conditions, not that fraud has been proved with 87% legal certainty.
The strongest systems combine several methods rather than relying on one model. Document classifiers can identify altered invoices or mismatched forms, while anomaly detection can compare a claim with expected claim behavior. Network analysis may reveal a provider connected to duplicate submissions, shared addresses, repeated bank accounts, or a cluster of claimants. Generative AI can summarize lengthy medical or loss records, but retrieval and summarization systems can still omit a crucial disclaimer, misread handwriting, or invent a connection between unrelated records. The Fraud Charter reporting cited in the research describes AI-generated activity as a possible “swamp” that can overwhelm fraud and complaints teams, which means a high alert volume is not automatically evidence of a high fraud rate. A model optimized to catch more fraud may generate so many false positives that investigators spend their time clearing ordinary claims.
The mathematical threshold also depends on the cost of each error. A 2% false-positive rate might be unacceptable in a system reviewing 1 million claims because it would misdirect 20,000 claims, even if it appears small. Precision measures how many flagged cases are genuine, while recall measures how many actual fraudulent cases the system detects. Insurers should evaluate both, along with the monetary value recovered, investigative labor saved, claimant harm caused, and the demographic consistency of outcomes. A system with 90% accuracy may still fail if it labels nearly every claimant as suspicious, targets a protected group disproportionately, or performs poorly on claims unlike its training data. Accuracy is therefore a starting point, not a sufficient procurement criterion.
Why Human Review Remains Necessary
Fraud is an intentional act, but an algorithmic signal is evidence about a pattern rather than direct evidence of intent. An implausibly short treatment timeline could reflect billing error, emergency treatment, an incorrect date entry, or fraud, and a claim investigator must determine which explanation fits. Human review is also needed because models can reproduce historical bias, including patterns embedded in past claim denials or provider investigations. Insurance Times reporting suggests that AI-generated fraudulent content can increase the volume of suspicious reports, while Insurance Business has warned that AI is making healthcare insurance fraud faster and less expensive in some cases. Those trends support using AI defensively, but they do not justify treating every anomaly as confirmed misconduct.
A competent reviewer should receive the score, the specific reasons for it, the records considered, the model’s confidence, and any known data-quality warnings. The reviewer should then compare those findings with the claim file and seek corroboration, such as original medical records, provider responses, identity evidence, repair photographs, police reports, or witness statements. The file should record whether the alert was confirmed, inconclusive, or erroneous and should explain the evidence supporting that conclusion. Appeals personnel should be able to see why a prior reviewer accepted the alert, because an unexplained score makes meaningful reconsideration difficult. If the claim was denied on subjective or behavioral grounds, the claimant must be told what decision was made, which information was used, and how to request review in ordinary language.
Human involvement must be more than a rubber stamp. A reviewer who must approve 300 flagged claims per day cannot meaningfully test each algorithmic conclusion, and managers who are rewarded only for reducing claim duration can pressure staff to ignore contrary evidence. Workload limits, independent quality sampling, and access to technical specialists are therefore part of fraud governance. The best practice is “human on the loop” for simple, well-supported cases and “human in the loop” for disputed, high-value, medically complex, or high-impact cases. Even with a human present, however, automation bias remains possible: reviewers may trust the score because it appears objective. Training should explicitly show examples of model errors and require staff to consider reasonable innocent explanations.
A Practical Claim Review Process
The first step is to classify the claim and determine the risk of automation. A duplicate digital invoice may be routed through a documented exception process, but a disputed disability benefit, large commercial property loss, or claim involving an ongoing medical condition should not be decided by an unreviewed algorithm. Before deployment, the insurer should establish the claim types in scope, the system’s intended use, the prohibited uses, the decision threshold, and the person accountable for each outcome. A claim-fraud platform should not quietly expand from identifying duplicate claims to recommending settlement amounts or eligibility decisions without a new validation. Every production change should be versioned so an investigator can determine which model and policy rules applied on the date of review.
The next step is an evidence-based investigation rather than a search for support for the model. Investigators should begin with the highest-value or clearest anomalies, then obtain source documents and contact relevant parties. Automated retrieval can assemble relevant claims, but external verification remains important when money or benefits are at stake. Decisions should follow a documented threshold: an alert may be cleared when an innocent explanation is verified, escalated when independent evidence supports fraud, and held for review when the evidence is incomplete. Insurers should not convert uncertainty into a finding simply to clear a backlog. Cases that cannot be resolved within the applicable review period should receive an impartial escalation, especially where delay itself could harm the claimant.
Continuous monitoring should compare results across claim types, geographies, providers, and relevant demographic groups. The insurer should review precision, false-positive rates, appeal reversals, investigation duration, fraud dollars recovered, and legitimate claims delayed at least 30, 60, or 90 days. The KUOW report about a private company using AI to review Washington Medicare claims illustrates the reputational and operational risk created by delayed processing: an algorithm that accelerates analysis can still become a bottleneck if records, explanations, or human capacity are missing. Regular audits should also test whether the model still performs well after billing codes, claim volumes, provider behavior, or document formats change. A model that was validated on 50,000 historical claims should not be assumed reliable simply because its original vendor test showed 95% accuracy.
| Feature | Rules-based screening | AI-assisted fraud review | Manual-only investigation |
|---|---|---|---|
| Typical use | Known duplicates, missing fields, fixed billing rules | Prioritization, anomaly detection, document and network analysis | Complex judgment, intent analysis, disputed evidence |
| Speed | Fast and predictable | Fast for large volumes | Slower and capacity-limited |
| Main strength | Transparent and easy to audit | Can detect complex patterns at scale | Better contextual judgment |
| Main weakness | Misses novel fraud patterns | Can amplify bias, errors, and false alerts | Inconsistent, expensive, and difficult to scale |
| Appropriate role | Precheck and clean claims | Investigator support and prioritization | Confirmation, appeal, and high-risk adjudication |
| Governance need | Clear rules and change logs | Validation, explanations, monitoring, and human override | Training, documentation, and quality review |
Insurers have several alternatives, and AI is not automatically the best one. Traditional business rules are cheaper and easier to explain when the fraud pattern is stable and known, while manual review remains preferable when the number of claims is modest or each case demands extensive judgment. Statistical outlier detection is useful for identifying unusual behavior without pretending to understand intent, and specialist investigators may outperform software on novel or socially engineered fraud. Managed detection services can provide experienced analysts and external fraud expertise, but they introduce vendor, data-sharing, and concentration risks. Insurers can also use multiple independent models, although an ensemble is not a cure when all models depend on the same inaccurate database.
Vendors frequently emphasize detection accuracy, recovered dollars, and hours saved, but these figures need careful interpretation. A claim “blocked” is not necessarily fraudulent, and money recovered is not automatically net savings once fees, appeals, legal expense, and investigator time are included. The Shift Technology funding example reported in 2021—$220 million at a valuation above $1 billion—illustrates substantial investor interest, but it is not evidence that any buyer’s deployment will achieve the same results. Buyers should ask for definitions of accuracy, precision, recall, false positives, prevented loss, confirmed recovery, and net benefit, then request results by relevant claim segment. A 20% reduction in review time is not a 20% fraud reduction, and a 30% reduction in flagged claims could reflect improved filtering or a model that has learned to stop reporting uncertain cases.
Common mistakes include selecting a system before defining the business problem, training on unreviewed historical decisions, and using a score as the sole basis for denial. Other errors are failing to check data quality, permitting a vendor to make final adverse decisions, failing to disclose the reasons for review, and setting an alert threshold without considering the cost of false positives. Insurers may also assume generative AI can replace investigators even when the task requires reliable interpretation of scanned or handwritten documents. Technical debt, cybersecurity exposure, model drift, and dependence on changing third-party APIs must be included in the total cost of ownership. A lower subscription price can still produce a poor result if staff must manually correct records, repeat investigations, or defend the insurer’s decision on appeal.
Costs, Timelines, and Decision Thresholds
There is no responsible universal market price because pricing depends on claim volume, data readiness, integrations, model type, deployment method, and whether the vendor or insurer performs investigation. In 2026, a small insurer might spend roughly $5,000 to $25,000 per year on a limited rules or SaaS screening product, while an enterprise platform, data feeds, integration, and managed service can cost from $100,000 to several million dollars annually. These are procurement ranges, not vendor quotes, and implementation cost can exceed the first-year subscription. A generative AI tool may add per-document, per-seat, or API usage charges, while managed investigators charge by claim, analyst hour, or recovered-dollar arrangement. The buyer should request a three-year total-cost model covering data preparation, security review, validation, appeals, licensing, infrastructure, and exit costs.
A typical implementation may take three to six months for a narrow, well-documented use case, while a complex enterprise deployment can require six to 18 months. The schedule should expand when claims data is inconsistent, legacy systems lack interfaces, or the insurer must redesign appeals and complaint handling. By 26 September 2026, AI Insurance Brokers can help compare platform capabilities, workflow fit, and expected deployment needs, but a broker should not replace legal, compliance, security, or actuarial review. The key question for management is whether the expected recovered fraud, avoided loss, and productivity benefit exceeds the full operating and claimant-impact cost. If the insurer cannot establish that baseline, the project may be premature.
A practical approval threshold can be built around evidence and impact rather than a single model probability. For example, claims above $25,000, claims involving continued medical treatment, or claims with prior reversals may automatically require senior human review. A low-value alert could be cleared only after two independent data checks, while a proposed adverse decision should require corroborating evidence and a second review. A useful pilot target is at least a 15% reduction in investigator hours per reviewed claim without increasing appeal reversals by more than two percentage points, although the insurer should set its own targets. Production should proceed only if the system remains accurate across relevant segments and staff can explain and override its recommendations. These numbers are examples of governance design, not universal regulatory requirements.
When to Act, Pause, or Escalate
An insurer should act now when it has a clearly defined fraud problem, sufficient claim history, capable staff, and a controlled way to measure results. A useful first project is duplicate billing, document matching, or prioritization of aged suspicious claims because these tasks have measurable outcomes and less risk than automated benefit denials. The insurer should also act when claim volumes have created backlogs, manual screening is inconsistent, and evidence indicates that a new tool can address a documented bottleneck. Regulatory attention, complaint trends, cyber exposure, and rising fraudulent AI-generated content make governance more urgent even when a full automation project is not justified. Waiting may be sensible when the vendor cannot provide data definitions, model documentation, test results, or contractual protections for data use.
The insurer should pause deployment after a material rise in false positives, a prolonged processing delay, an unexplained increase in adverse outcomes, or evidence that the model performs unevenly across relevant populations. It should also pause if staff are overriding the model on more than half of flagged claims, because that level of disagreement usually indicates a data, threshold, or workflow failure. Escalate individual claims to a qualified human when the model and documents conflict, the evidence indicates intentional deception, or the decision could affect urgent medical care, income replacement, or essential coverage. A formal incident process should preserve the model version, inputs, output, reviewer action, and any corrective communication. The purpose is not to silence a model; it is to ensure that consequential decisions remain contestable and legally defensible.
Ultimately, insurers should use AI to make fraud review more systematic, faster to investigate, and better documented. They should not use it to manufacture certainty where the available evidence is incomplete. A defensible system combines validated data, transparent rules, independent testing, meaningful human authority, claimant notice, appeal access, and continuous monitoring. It reports false positives and prevented losses as well as suspected fraud, and it keeps a human accountable for every adverse decision. The strongest position in 2026 is neither prohibition nor unrestricted automation, but controlled assistance with clear accountability.